452
H. Jin
85. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy
JM, Boufakhreddine S, Holohan TV, Schaub RG (2007) First-in-human evaluation of anti
von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation
116(23):2678–2686. https://doi.org/10.1161/circulationaha.107.724864
86. Spiel AO, Mayr FB, Ladani N, Wagner PG, Schaub RG, Gilbert JC, Jilma B (2009) The
aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo
platelet function in acute myocardial infarction. Platelets 20(5):334–340. https://doi.org/10.
1080/09537100903085927
87. Adams HP Jr (2003) Stroke: a vascular pathology with inadequate management. J Hypertens
21:S3–S7
88. Nimjee SM, Dornbos D 3rd, Pitoc GA, Wheeler DG, Layzer JM, Venetos N, Huttinger A,
Talentino SE, Musgrave NJ, Moody H, Rempel RE, Jones C, Carlisle K, Wilson J, Bratton
C, Joseph ME, Khan S, Hoffman MR, Sommerville L, Becker RC, Zweier JL, Sullenger
BA (2019) Preclinical development of a vWF aptamer to limit thrombosis and engender
arterial recanalization of occluded vessels. Mol Ther 27(7):1228–1241. https://doi.org/10.
1016/j.ymthe.2019.03.016
89. Povsic TJ, Vavalle JP, Aberle LH, Kasprzak JD, Cohen MG, Mehran R, Bode C, Buller CE,
Montalescot G, Cornel JH, Rynkiewicz A, Ring ME, Zeymer U, Natarajan M, Delarche N,
Zelenkofske SL, Becker RC, Alexander JH (2013) A Phase 2, randomized, partially blinded,
active-controlled study assessing the efficacy and safety of variable anticoagulation reversal
using the REG1 system in patients with acute coronary syndromes: results of the RADAR
trial. Eur Heart J 34(31):2481–2489. https://doi.org/10.1093/eurheartj/ehs232
90. Vacca VM Jr (2019) Acquired autoimmune thrombotic thrombocytopenic purpura. Nursing
49(1):22–29. https://doi.org/10.1097/01.NURSE.0000549721.69197.4d
91. Cataland SR, Peyvandi F, Mannucci PM, Lämmle B, Kremer Hovinga JA, Machin SJ, Scully
M, Rock G, Gilbert JC, Yang S, Wu H, Jilma B, Knoebl P (2012) Initial experience from a
double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol 87(4):430–432. https://doi.org/10.1002/ajh.
23106
92. Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernández C, VargasCastrillón E (2011) New parenteral anticoagulants in development. Ther Adv Cardiovasc
Dis 5(1):33–59. https://doi.org/10.1177/1753944710387808
93. Sakai K, Someya T, Harada K, Yagi H, Matsui T, Matsumoto M (2019) Novel aptamer to von
Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation
superior to ARC1779 and comparable to caplacizumab. Haematologica. https://doi.org/10.
3324/haematol.2019.235549
94. Suh SH, Choi SJ, Dwivedi HP, Moore MD, Escudero-Abarca BI, Jaykus LA (2018) Use
of DNA aptamer for sandwich type detection of Listeria monocytogenes. Anal Biochem
557:27–33. https://doi.org/10.1016/j.ab.2018.04.009
95. Borghei YS, Hosseini M, Dadmehr M, Hosseinkhani S, Ganjali MR, Sheikhnejad R (2016)
Visual detection of cancer cells by colorimetric aptasensor based on aggregation of gold
nanoparticles induced by DNA hybridization. Anal Chim Acta 904:92–97. https://doi.org/10.
1016/j.aca.2015.11.026
96. Nicol C, Cesur Ö, Forrest S, Belyaeva TA, Bunka DH, Blair GE, Stonehouse NJ (2013) An
RNA aptamer provides a novel approach for the induction of apoptosis by targeting the HPV16
E7 oncoprotein. PLoS ONE 8(5):e64781. https://doi.org/10.1371/journal.pone.0064781
97. Cesur Ö, Nicol C, Groves H, Mankouri J, Blair GE, Stonehouse NJ (2015) The subcellular
localisation of the human papillomavirus (HPV) 16 E7 protein in cervical cancer cells and its
perturbation by RNA aptamers. Viruses 7(7):3443–3461. https://doi.org/10.3390/v7072780
98. Valencia-Reséndiz DG, Palomino-Vizcaino G, Tapia-Vieyra JV, Benítez-Hess ML, LeijaMontoya AG, Alvarez-Salas LM (2018) Inhibition of human papillomavirus type 16 infection
using an RNA aptamer. Nucl Acid Ther 28(2):97–105. https://doi.org/10.1089/nat.2017.0687
99. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO (2009) Discovery and development of
the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86(3):151–
164. https://doi.org/10.1016/j.yexmp.2009.01.004
H. Jin
85. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy
JM, Boufakhreddine S, Holohan TV, Schaub RG (2007) First-in-human evaluation of anti
von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation
116(23):2678–2686. https://doi.org/10.1161/circulationaha.107.724864
86. Spiel AO, Mayr FB, Ladani N, Wagner PG, Schaub RG, Gilbert JC, Jilma B (2009) The
aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo
platelet function in acute myocardial infarction. Platelets 20(5):334–340. https://doi.org/10.
1080/09537100903085927
87. Adams HP Jr (2003) Stroke: a vascular pathology with inadequate management. J Hypertens
21:S3–S7
88. Nimjee SM, Dornbos D 3rd, Pitoc GA, Wheeler DG, Layzer JM, Venetos N, Huttinger A,
Talentino SE, Musgrave NJ, Moody H, Rempel RE, Jones C, Carlisle K, Wilson J, Bratton
C, Joseph ME, Khan S, Hoffman MR, Sommerville L, Becker RC, Zweier JL, Sullenger
BA (2019) Preclinical development of a vWF aptamer to limit thrombosis and engender
arterial recanalization of occluded vessels. Mol Ther 27(7):1228–1241. https://doi.org/10.
1016/j.ymthe.2019.03.016
89. Povsic TJ, Vavalle JP, Aberle LH, Kasprzak JD, Cohen MG, Mehran R, Bode C, Buller CE,
Montalescot G, Cornel JH, Rynkiewicz A, Ring ME, Zeymer U, Natarajan M, Delarche N,
Zelenkofske SL, Becker RC, Alexander JH (2013) A Phase 2, randomized, partially blinded,
active-controlled study assessing the efficacy and safety of variable anticoagulation reversal
using the REG1 system in patients with acute coronary syndromes: results of the RADAR
trial. Eur Heart J 34(31):2481–2489. https://doi.org/10.1093/eurheartj/ehs232
90. Vacca VM Jr (2019) Acquired autoimmune thrombotic thrombocytopenic purpura. Nursing
49(1):22–29. https://doi.org/10.1097/01.NURSE.0000549721.69197.4d
91. Cataland SR, Peyvandi F, Mannucci PM, Lämmle B, Kremer Hovinga JA, Machin SJ, Scully
M, Rock G, Gilbert JC, Yang S, Wu H, Jilma B, Knoebl P (2012) Initial experience from a
double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol 87(4):430–432. https://doi.org/10.1002/ajh.
23106
92. Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernández C, VargasCastrillón E (2011) New parenteral anticoagulants in development. Ther Adv Cardiovasc
Dis 5(1):33–59. https://doi.org/10.1177/1753944710387808
93. Sakai K, Someya T, Harada K, Yagi H, Matsui T, Matsumoto M (2019) Novel aptamer to von
Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation
superior to ARC1779 and comparable to caplacizumab. Haematologica. https://doi.org/10.
3324/haematol.2019.235549
94. Suh SH, Choi SJ, Dwivedi HP, Moore MD, Escudero-Abarca BI, Jaykus LA (2018) Use
of DNA aptamer for sandwich type detection of Listeria monocytogenes. Anal Biochem
557:27–33. https://doi.org/10.1016/j.ab.2018.04.009
95. Borghei YS, Hosseini M, Dadmehr M, Hosseinkhani S, Ganjali MR, Sheikhnejad R (2016)
Visual detection of cancer cells by colorimetric aptasensor based on aggregation of gold
nanoparticles induced by DNA hybridization. Anal Chim Acta 904:92–97. https://doi.org/10.
1016/j.aca.2015.11.026
96. Nicol C, Cesur Ö, Forrest S, Belyaeva TA, Bunka DH, Blair GE, Stonehouse NJ (2013) An
RNA aptamer provides a novel approach for the induction of apoptosis by targeting the HPV16
E7 oncoprotein. PLoS ONE 8(5):e64781. https://doi.org/10.1371/journal.pone.0064781
97. Cesur Ö, Nicol C, Groves H, Mankouri J, Blair GE, Stonehouse NJ (2015) The subcellular
localisation of the human papillomavirus (HPV) 16 E7 protein in cervical cancer cells and its
perturbation by RNA aptamers. Viruses 7(7):3443–3461. https://doi.org/10.3390/v7072780
98. Valencia-Reséndiz DG, Palomino-Vizcaino G, Tapia-Vieyra JV, Benítez-Hess ML, LeijaMontoya AG, Alvarez-Salas LM (2018) Inhibition of human papillomavirus type 16 infection
using an RNA aptamer. Nucl Acid Ther 28(2):97–105. https://doi.org/10.1089/nat.2017.0687
99. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO (2009) Discovery and development of
the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86(3):151–
164. https://doi.org/10.1016/j.yexmp.2009.01.004